Drug Profile
Epoetin omega
Alternative Names: Epomax; Epomega; Hemax (Epoetin omega)Latest Information Update: 15 Jan 2019
Price :
$50
*
At a glance
- Originator Elanex Pharma Group
- Class Antianaemics; Recombinant erythropoietins
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Anaemia
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 03 Jun 2016 Baxalta has been acquired and merged into Shire
- 31 Dec 2004 Discontinued - Phase-II for Anaemia in Japan (Injection)